With Ranbaxy Under Belt, Sun Eyes Fast Track Global Growth
This article was originally published in PharmAsia News
Sun and Ranbaxy have finally combined into a single global company, but that could be just the beginning of a series of fresh challenges. Sun said it will look at growing its businesses faster than the industry average in most key markets, and at the same time look to remediate the troubled manufacturing sites of Ranbaxy. Management also indicated that it might not appeal against the recent U.S. Court ruling on generic Nexium.
You may also be interested in...
But court finds FDA has authority to correct its mistakes and revoke Ranbaxy’s tentative ANDA approvals
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.